{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460018936
| IUPAC_name = (5''Z'',9α,11α,13''E'',15''S'')-9,11,15-trihydroxy-15- methylprosta-5,13-dien-1-oic acid
| image = Carboprost.svg
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|CONS|carboprost}}
| MedlinePlus = a600042
| pregnancy_category = c
| legal_status = Rx-only
| routes_of_administration = Intramuscular
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 35700-23-3
| ATC_prefix = G02
| ATC_suffix = AD04
| ATC_supplemental =
| PubChem = 5281075
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00429
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444532
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U4526F86FJ
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1237122
<!--Chemical data-->
| C=21 | H=36 | O=5
| molecular_weight = 368.508 g/mol
| smiles = O=C(O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@](O)(C)CCCCC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H36O5/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25)/b7-5-,14-12+/t16-,17-,18+,19-,21+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DLJKPYFALUEJCK-IIELGFQLSA-N
|drug_name=|alt=|caption=|type=|licence_EU=|pregnancy_AU=|pregnancy_US=|licence_US=}}

'''Carboprost''' ([[International Nonproprietary Name|INN]], trade names for the [[tromethamine]] salts '''Hemabate''', '''Tham''') is a synthetic [[prostaglandin]] analogue of [[Prostaglandin F2alpha|PGF<sub>2α</sub>]] (specifically, it is 15-methyl-PGF<sub>2α</sub>) with [[oxytocic]] properties.

Carboprost induces [[Contraction (childbirth)|contractions]] and can trigger abortion in early pregnancy. It also reduces [[postpartum bleeding]].

== Indication ==
Used in postpartum hemorrhage caused by uterine atony not controlled by other methods. One study has shown that carboprost tromethamine is more effective than oxytocin in preventing postpartum hemorrhage in high-risk patients undergoing cesarean delivery.<ref>{{cite journal|last=Bai|first=J|author2=Sun, Q|author3=Zhai, H|title=A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery.|journal=Journal of Experimental and Therapeutic Medicine|year=2014|volume=7|issue=1|pages=46–50|pmid=24348762|doi=10.3892/etm.2013.1379|pmc=3861477}}</ref> Carboprost is also used for the termination of pregnancy in the 2nd trimester.<ref name = HemabatePI>Hemabate [Package Insert]. New York, NY: Pharmacia and Upjohn Company; 2014.</ref>

Unlabeled use:
* Hemorrhagic Cystitis
* PID

== Contraindication ==
Contraindicated in severe cardiovascular, renal, and hepatic disease. It is also contraindicated in acute Pelvic Inflammatory Disease. Hypersensitivity to carboprost or any of its components is also a contraindication<ref name = HemabatePI /> Exert caution in asthmatic patients as carboprost may cause bronchospasm.

== Precautions ==
* asthma
* anemia
* jaundice
* diabetes mellitus
* seizure disorders
* past uterine surgery

== Adverse Effects ==
* diarrhea (most common, may be sudden in onset)
* flushing or hot flashes
* fever
* chills
* nausea/vomiting

== Storage and Availability ==
Carboprost is supplied with its salt derivative tromethamine in 1 milliliter ampules containing a 250 microgram/milliliter solution of the active drug. The drug must be refrigerated at a temperature between 2 – 8 degrees Celsius.<ref name = HemabatePI />

== Synthesis ==
A significant deactivating metabolic transformation of natural prostaglandins is enzymatic oxidation of the C-15 hydroxyl to the corresponding ketone. This is prevented, with retention of activity, by methylation to give the C-15 tertiary carbinol series.
[[File:Carboprost synthesis.svg|thumb|center|750px|Carboprost synthesis:<ref>{{cite journal|doi=10.1021/ja00825a027|pmid=4416671|title=Total synthesis of 15-methylprostaglandins|journal=Journal of the American Chemical Society|volume=96|issue=18|pages=5865|year=1974|last1=Yankee|first1=Ernest W.|last2=Axen|first2=Udo|last3=Bundy|first3=Gordon L.}}</ref><ref>{{cite journal | last1 = | first1 =  | year = 1971 | title =  NOVEL PROSTAGLANDIN SYNTHESES| doi = 10.1111/j.1749-6632.1971.tb53186.x | journal = Ann. N.Y. Acad. Sci. | volume = 180 | issue = | page = 76 }}</ref> G. L. Bundy et al., {{cite patent|DE|2121980}}; G. L. Bundy, {{US patent|3728382}} (1971, 1973 both to [[Upjohn]]).]]
This molecular feature is readily introduced at the stage of the Corey lactone ('''1''') by reaction with methyl [[Grignard reagent]] or [[trimethylaluminium]]. The resulting mixture of tertiary carbinols ('''2''') is transformed to oxytocic carboprost ('''3''') by standard transformations, including sepoaration of diastereomers, so that the final product is the C-15 analogue. This diastereomer is reputably freeer of porstaglandin side effects than the C-15 (S) isomer.

== See also ==
*[[Arbaprostil]]

== References ==
{{reflist}}

== External links ==
* {{MeshName|Carboprost}}
* {{cite journal | author = Indman P | title = Use of carboprost to facilitate hysteroscopic resection of submucous myomas| journal = J Am Assoc Gynecol Laparosc | volume = 11 | issue = 1 | pages = 68–72 | year = 2004 | pmid = 15104835 | doi = 10.1016/S1074-3804(05)60014-X}}
* {{cite journal | author = Vukelić J | title = Second trimester pregnancy termination in primigravidas by double application of dinoprostone gel and intramuscular administration of carboprost tromethamine| journal = Med Pregl | volume = 54 | issue = 1–2 | pages = 11–6 | year = 2001| pmid = 11436877}}
* {{cite journal |vauthors=Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B | title = Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation | journal = Urology | volume = 46 | issue = 6 | pages = 811–5 | year = 1995 | pmid = 7502421 | doi = 10.1016/S0090-4295(99)80349-5}}

{{Prostaglandins}}
{{Oxytocics}}
{{Prostanoidergics}}

[[Category:Orphan drugs]]
[[Category:Prostaglandins]]


{{genito-urinary-drug-stub}}